Product Description
Zalcitabine is an analogue of the nucleoside deoxycytidine which, when intracellularly converted to an active triphosphate metabolite, inhibits replication of human immunodeficiency virus (HIV). Zalcitabine is thought to act in the early phase of HIV replication by inhibiting reverse transcriptase and terminating the viral DNA chain. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/1281077/)
Mechanisms of Action: DNA Polymerase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Approved
Approved Countries: Brazil | Canada | Chile | Colombia | Germany | India | Ireland | Italy | New Zealand | Pakistan | Peru | Portugal | Slovenia | Taiwan | United Kingdom | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/31/2022 |
News Article |
Gain Therapeutics Announces Additional Details on its February 4th Virtual R&D Day |
|
04/15/2019 |
News Article |
Sensei Biotherapeutics Appoints Former Head of the National Cancer Institute, Samuel Broder, M.D. to its Board of Directors |